Investment Analysts’ Updated EPS Estimates for February 19th (ABEO, AEMD, AML, ANDE, ANET, AXSM, AZN, BA, BIDU, CDNS)

Investment Analysts’ updated eps estimates for Wednesday, February 19th:

Abeona Therapeutics (NASDAQ:ABEO) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $15.00 price target on the stock.

Aethlon Medical (NASDAQ:AEMD) had its buy rating reissued by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.

Aston Martin Lagonda Global (LON:AML) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. They currently have a GBX 160 ($2.02) target price on the stock.

Andersons (NASDAQ:ANDE) had its overweight rating reissued by analysts at Stephens. They currently have a $55.00 target price on the stock.

Arista Networks (NYSE:ANET) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $145.00 price target on the stock.

Arista Networks (NYSE:ANET) had its neutral rating reiterated by analysts at Piper Sandler. They currently have a $108.00 target price on the stock, up from their previous target price of $106.00.

Axsome Therapeutics (NASDAQ:AXSM) had its overweight rating reissued by analysts at Cantor Fitzgerald. The firm currently has a $153.00 target price on the stock.

AstraZeneca (LON:AZN) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co..

BAE Systems (LON:BA) had its buy rating reissued by analysts at Berenberg Bank. The firm currently has a GBX 1,440 ($18.17) price target on the stock.

Baidu (NASDAQ:BIDU) had its buy rating reiterated by analysts at Benchmark Co.. The firm currently has a $130.00 target price on the stock.

Cadence Design Systems (NASDAQ:CDNS) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $325.00 price target on the stock.

CRISPR Therapeutics (NASDAQ:CRSP) had its neutral rating reissued by analysts at Cantor Fitzgerald.

CoStar Group (NASDAQ:CSGP) had its sector perform rating reiterated by analysts at Royal Bank of Canada. They currently have a $83.00 target price on the stock.

CoStar Group (NASDAQ:CSGP) had its outperform rating reiterated by analysts at William Blair.

Bright Minds Biosciences (NASDAQ:DRUG) had its buy rating reissued by analysts at HC Wainwright. They currently have a $85.00 price target on the stock.

Precision BioSciences (NASDAQ:DTIL) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $60.00 price target on the stock.

Expeditors International of Washington (NASDAQ:EXPD) had its hold rating reissued by analysts at Benchmark Co..

FirstCash (NASDAQ:FCFS) had its overweight rating reiterated by analysts at Stephens. They currently have a $137.00 target price on the stock.

Shift4 Payments (NYSE:FOUR) had its overweight rating reiterated by analysts at Stephens. The firm currently has a $125.00 price target on the stock.

Shift4 Payments (NYSE:FOUR) had its overweight rating reiterated by analysts at Piper Sandler. Piper Sandler currently has a $143.00 price target on the stock, up from their previous price target of $120.00.

Fiverr International (NYSE:FVRR) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $36.00 target price on the stock.

Hillman Solutions (NASDAQ:HLMN) had its buy rating reissued by analysts at Benchmark Co.. They currently have a $16.00 target price on the stock.

Honest (NASDAQ:HNST) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. The firm currently has a $7.00 price target on the stock.

Harmony Biosciences (NASDAQ:HRMY) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $75.00 price target on the stock.

Imunon (NASDAQ:IMNN) had its buy rating reaffirmed by analysts at D. Boral Capital. The firm currently has a $29.00 target price on the stock.

Insmed (NASDAQ:INSM) had its overweight rating reiterated by analysts at Cantor Fitzgerald.

iQIYI (NASDAQ:IQ) had its hold rating reaffirmed by analysts at Benchmark Co..

Opus Genetics (NASDAQ:IRD) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $8.00 price target on the stock.

Johnson & Johnson (NYSE:JNJ) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $181.00 price target on the stock.

Krystal Biotech (NASDAQ:KRYS) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $221.00 target price on the stock.

Lincoln Educational Services (NASDAQ:LINC) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $20.00 price target on the stock.

Light & Wonder (NASDAQ:LNW) had its buy rating reiterated by analysts at Benchmark Co.. The firm currently has a $114.00 target price on the stock.

Medtronic (NYSE:MDT) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $105.00 target price on the stock.

Medtronic (NYSE:MDT) had its hold rating reiterated by analysts at Needham & Company LLC.

NIKE (NYSE:NKE) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. The firm currently has a $80.00 price target on the stock.

Occidental Petroleum (NYSE:OXY) had its overweight rating reissued by analysts at Stephens. They currently have a $71.00 price target on the stock.

Penumbra (NYSE:PEN) had its hold rating reaffirmed by analysts at Needham & Company LLC.

Penumbra (NYSE:PEN) had its overweight rating reissued by analysts at Piper Sandler. Piper Sandler currently has a $330.00 target price on the stock, up from their previous target price of $250.00.

Phio Pharmaceuticals (NASDAQ:PHIO) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $4.00 target price on the stock.

Redfin (NASDAQ:RDFN) had its neutral rating reaffirmed by analysts at DA Davidson. DA Davidson currently has a $7.25 price target on the stock.

Rush Enterprises (NASDAQ:RUSHA) had its overweight rating reaffirmed by analysts at Stephens. Stephens currently has a $69.00 target price on the stock.

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $64.00 price target on the stock.

Safe Bulkers (NYSE:SB) had its buy rating reaffirmed by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $6.00 target price on the stock.

Sapiens International (NASDAQ:SPNS) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $35.00 price target on the stock.

Stoke Therapeutics (NASDAQ:STOK) had its buy rating reaffirmed by analysts at Chardan Capital. They currently have a $24.00 target price on the stock.

TJX Companies (NYSE:TJX) had its outperform rating reaffirmed by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $145.00 price target on the stock.

Tracsis (LON:TRCS) had its buy rating reissued by analysts at Berenberg Bank. The firm currently has a GBX 1,150 ($14.51) price target on the stock.

UFP Industries (NASDAQ:UFPI) had its buy rating reiterated by analysts at Benchmark Co.. They currently have a $135.00 target price on the stock.

Urban Outfitters (NASDAQ:URBN) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $56.00 target price on the stock.

VYNE Therapeutics (NASDAQ:VYNE) had its buy rating reissued by analysts at HC Wainwright. They currently have a $5.75 target price on the stock.

Wingstop (NASDAQ:WING) had its overweight rating reaffirmed by analysts at Stephens. Stephens currently has a $450.00 price target on the stock.

Wix.com (NASDAQ:WIX) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $235.00 price target on the stock.

Wolverine World Wide (NYSE:WWW) had its market perform rating reissued by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $23.00 target price on the stock.